Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.

The emerging role of the endocannabinoid system in cardiovascular disease.

Authors: Pál Pacher, Sabine Steffens
Seminars in Immunopathology, June 2009

Endocannabinoids are endogenous bioactive lipid mediators present both in the brain and various peripheral tissues, which exert their biological effects via interaction with specific G-protein-coupled cannabinoid receptors, the CB(1) and CB(2). Pathological overactivation of t…

Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse.

Authors: Siva P. Sontineni, Sanjay Chaudhary, Vijaya Sontineni, Stephen J. Lanspa
World Journal of Gastroenterology, 14 March 2009

Cannabis is a common drug of abuse that is associated with various long-term and short-term adverse effects. The nature of its association with vomiting after chronic abuse is obscure and is underrecognised by clinicians. In some patients this vomiting can take on a pattern si…

The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).

Authors: George A. Fraser
CNS Neuroscience & Therapeutics, Winter 2009

This is the report of an open label clinical trial to evaluate the effects of nabilone, an endocannabinoid receptor agonist, on treatment-resistant nightmares in patients diagnosed with posttraumatic stress disorder (PTSD). METHODS: Charts of 47 patients diagnosed with PTSD an…

Neuroanatomic comparison of bipolar adolescents with and without cannabis use disorders.

Authors: Kelly Jarvis, Melissa P. DelBello, Neil Mills, Igor Elman, Stephen M. Strakowski, Caleb M. Adler
Journal of Child and Adolescent Psychopharmacology, December 2008

OBJECTIVE: Co-occurrence of substance use and bipolar disorders is both common and associated with poor treatment response and greater functional impairment than either disorder alone. The neurophysiological correlates of this co-morbidity however, remain unclear. In this pilo…

Cannabis Treatments in Obstetrics and Gynecology: A Historical Review.

Authors: Ethan Russo
Journal of Cannabis Therapeutics, October 2008

Cannabis has an ancient tradition of usage as a medicine in obstetrics and gynecology. This study presents that history in the literature to the present era, compares it to current ethnobotanical, clinical and epidemiological reports, and examines it in light of modern develop…

Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study.

Authors: Mia Hashibe, Hal Morgenstern, Yan Cui, Donald P. Tashkin, Zuo-Feng Zhang, et al
Cancer Epidemiology Biomarkers & Prevention, October 2008

BACKGROUND: Despite several lines of evidence suggesting the biological plausibility of marijuana being carcinogenic, epidemiologic findings are inconsistent. We conducted a population-based case-control study of the association between marijuana use and the risk of lung and u…

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Authors: Antonio Waldo Zuardi
Brazilian Journal of Psychiatry, September 2008

OBJECTIVE: The aim of this review is to describe the historical development of research on cannabidiol. METHOD: This review was carried out on reports drawn from Medline, Web of Science and SciELO. DISCUSSION: After the elucidation of the chemical structure of cannabidiol in 1…

Cannabinoid receptors in human astroglial tumors.

Authors: Janka Held‐Feindt, Lutz Dörner, Gülcan Sahan,H. Maximilian Mehdorn, Rolf Mentlein
Journal of Neurochemistry, August 2008

In animal models, cannabinoids are reported to inhibit the growth of tumors, including gliomas. These effects have been claimed to be mediated via cannabinoid receptors 1 and 2 (CB1, CB2). To elucidate a possible relevance for treatment of human gliomas, we investigated recept…

Multiple roles for the endocannabinoid system during the earliest stages of life: pre- and postnatal development.

Authors: Ester Fride
Journal of Neuroendocrinology, May 2008

The endocannabinoid system, including its receptors (CB(1) and CB(2)), endogenous ligands (‘endocannabinoids’), synthesising and degrading enzymes, as well as transporter molecules, has been detected from the earliest stages of embryonic development and throughout pre- and pos…

Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis.

Authors: Denise Richardson, Richard G. Pearson, Nisha Kurian, M. Liaque Latif, Michael J. Garle, et al
Arthritis Research & Therapy, April 2008

INTRODUCTION: Cannabis-based medicines have a number of therapeutic indications, including anti-inflammatory and analgesic effects. The endocannabinoid receptor system, including the cannabinoid receptor 1 (CB1) and receptor 2 (CB2) and the endocannabinoids, are implicated in…

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Authors: Ethan Budd Russo
Neuroendocrinology Letters, April 2008

OBJECTIVES: This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. METHODS:…

Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring.

Authors: Vincent Maida, Marguerite Ennis, Shiraz Irani, Mario Corbo, Michael Dolzhykov
Journal of Supportive Oncology, March 2008

A prospective observational study assessed the effectiveness of adjuvant nabilone (Cesamet) therapy in managing pain and symptoms experienced by advanced cancer patients. The primary outcomes were the differences between treated and untreated patients at 30 days’ follow-up, in…